Navigation Links
Personalized molecular therapy shows promising results for people with advanced lung cancer
Date:12/9/2010

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.

Epigenetics therapy is an approach designed to control the expression of good and bad genes that influence the development of resistance to targeted therapies. This study, called ENCORE 401, was designed to evaluate whether entinostat, a novel epigenetic therapy that is given orally, can be used to delay or overcome the resistance to erlotinib in patients with advanced lung cancer.

This study was a randomized phase II placebo controlled clinical trial in advanced lung cancer examining whether entinostat in combination with erlotinib is better than erlotinib alone and whether it can be safely tolerated by patients. As part of the clinical trial, patients underwent an analysis of various tissue and blood biomarkers. The results demonstrated that patients with elevated E-cadherin (a molecular marker) who were administered entinostat in combination with erlotinib had a significantly improved overall survival as compared to patients treated with erlotinib alone. Approximately 40 percent of non-small cell lung cancer patients have elevated E-cadherin.

These findings highlight the importance of patient selection in defining treatment approaches in lung cancer and, if confirmed, could provide benefit to patients who have or develop resistance to current molecular targeted therapy.

"The results of ENCORE 401 identified a subset of lung cancer patients for whom the combination of epigenetic therapy, entinostat and molecular targeted therapy, erlotinib, achieved promising result
'/>"/>

Contact: Beth Bukata
bethb@astro.org
703-431-2332
American Society for Radiation Oncology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years
2. Personalized medicine: Tumor analysis reveals new opportunities for existing cancer drugs
3. New venture explores frontiers of personalized medicine
4. Personalized treatment may help some liver cancer patients
5. Perspectives on improving patient care: Genetics, personalized medicine, and behavioral intervention
6. Penn receives $12 million NIH grant to research personalized approach to smoking cessation
7. Personalized medicine: Molecular imaging predicts treatment success in many cancers
8. Pilot study supports adolescent diabetes patients through personalized text messages
9. Tumor target suggests personalized treatment for melanoma
10. Advances in personalized medicine take center stage
11. Myth Debunked: Baby Shower Gifts CAN Be Personalized Without Knowing Name Or Gender
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... 01, 2015 , ... The integration of Practice Perfect and ... Perfect to FOTO enabling cost and time savings, reducing errors and omissions, and ... of Practice Perfect, stated "FOTO is a natural extension of Practice Perfect, ...
(Date:9/1/2015)... ... 01, 2015 , ... Elizabeth Callahan, MD, founder and medical director of ... to offer RADIESSE® filler treatment for volume loss in the hands. RADIESSE provides an ... in the hands, delivering smooth, natural-looking results that can last up to one year ...
(Date:9/1/2015)... ... ... every family has them. Whether it’s a morning routine, meal time routine or weekly ... Here are three reasons why routines can be beneficial for a child: , 1. ... implemented into a child’s schedule, they are able to anticipate what will happen next ...
(Date:9/1/2015)... ... September 01, 2015 , ... MediNatura™, the exclusive ... workshop for physician assistants (PAs) practicing in orthopedics. The workshop, titled “Treatment of ... by Dr. Erick Salado, an orthopedic surgeon at South Florida Bone and Joint ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for ... to understand the scope of their EHS regulatory obligations and rapidly collect, share, ...
Breaking Medicine News(10 mins):Health News:FOTO Announces New Integration Partnership with Practice Perfect 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:Back into the Swing of Things: How Family Routines Benefit Children 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 3Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 2Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 3Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 4
... to Honor Qualcomm CEOSAN DIEGO, May 11 , WHAT: ... organization is undertaking to make 211 a nationwide service, ... plays in the community during, ... resources at Join Our Journey event. 211 ...
... 11 The Ensign Group, Inc. (Nasdaq: ... Ensign(TM) group of skilled nursing, rehabilitative care services ... will participate in the Eighth Annual JMP Securities ... Ritz-Carlton in San Francisco. (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO )Christopher ...
... Opinion to Comply with NASDAQ Marketplace Rule 4350(b)(1)(B)WAYNE, ... (Nasdaq: ENCO ), a full ... design, development, and management capabilities for clinical trials ... leading pharmaceutical companies, today announced that it has ...
... Corporation announced today that for the quarter ended March 31, 2009, ... per share, on revenues of $5.2 million compared to a net ... of $5.2 million in the previous year. The loss from continuing ... compared to income of $3.2 million for the same period in ...
... , Montreal, May 11, 2009 When it ... equal hand. The latest study by Dr. Maya Saleh, of ... McGill University, shows that women have a more powerful immune ... females could have a beneficial effect on the innate inflammatory ...
... Healthcare Realty Trust Incorporated (NYSE: HR ) today ... March 31, 2009. This dividend, in the amount of ... shareholders of record on May 22, 2009. The total ... flows from operations determined in accordance with GAAP. The ...
Cached Medicine News:Health News:211 San Diego Provides Support to San Diegans in Times of Crisis 2Health News:The Ensign Group to Present at the Eighth Annual JMP Securities Research Conference on May 19th 2Health News:The Ensign Group to Present at the Eighth Annual JMP Securities Research Conference on May 19th 3Health News:Encorium Group Enters into Non-Binding Letters of Intent 2Health News:Encorium Group Enters into Non-Binding Letters of Intent 3Health News:Encorium Group Enters into Non-Binding Letters of Intent 4Health News:Encorium Group Enters into Non-Binding Letters of Intent 5Health News:Westaim announces 2009 first quarter results 2Health News:Westaim announces 2009 first quarter results 3Health News:Equality of the sexes? Not always when it comes to biology 2Health News:Healthcare Realty Trust Announces First Quarter Dividend 2Health News:Healthcare Realty Trust Announces First Quarter Dividend 3Health News:Healthcare Realty Trust Announces First Quarter Dividend 4
(Date:8/31/2015)...  On August 5, 2015, the U.S. District Court ... denied motions to dismiss securities class action claims against ... of its directors. The class actions allege that the ... to artificially inflate Galena,s stock price, and during an ... inflated, sold massive amounts of their personally-held shares. ...
(Date:8/31/2015)... , Aug. 31, 2015 Regen BioPharma, ... development of a novel means of delivering its ... RGBP-248, to liver tumors utilizing a clinically approved ... overcomes previous hurdles with gene silencing therapeutics in ... delivered throughout the whole body.  By utilizing a ...
(Date:8/31/2015)... DIEGO , Aug. 31, 2015  Qualcomm ... its subsidiary, Qualcomm Life, Inc., is ... develop chronic care management solutions powered by Qualcomm ... Coordination Platform to enable continuous care, informed interventions ... were announced at Qualcomm Life,s annual Connect ...
Breaking Medicine Technology:Galena Biopharma, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches of Fiduciary Duty 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... April 18, 2011 Altitude Organic Corporation (Pinksheets: ... announced today that it has launched its third-party ... headquarters.  Visit the DoctorMMJ.com website ( www.DoctorMMJ.com ) ... and entirely legal medical marijuana evaluation in Arizona. ...
... 2011 Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ... Administration (FDA) has accepted for review the Company,s Biologics ... of the neovascular form of age-related macular degeneration (wet ... priority review of its BLA.  A Priority Review designation ...
Cached Medicine Technology:Altitude Organic Corporation Opens DoctorMMJ.com Physician Referral Service in Scottsdale, Arizona 2Altitude Organic Corporation Opens DoctorMMJ.com Physician Referral Service in Scottsdale, Arizona 3FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 2FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: